← boardnext 2026-09-17next 2026-10-30next 2026-12-30next 2027-01-25next 2027-02-02next 2027-03-12next 2027-03-25next 2027-04-06next 2027-06-06next 2027-06-30next 2027-07-22next 2028-01-30next 2028-06-02next 2029-07-30
VRTX
Vertex Pharmaceuticals Incorporateddistress 1/10 · well-funded / low risk$469.20-1%today-11% from 52w high
Lead: Cystic Fibrosis · est. market ~$10B (approx, global)
Revenue
$2987M
Liquidity
$12997M
Runway
—
Shares 1y
-1%
Price & events
+0.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-3.5%
1W
+0.2%
1M
+7.8%
3M
+0.2%
6M
-1.6%
1Y
-4.3%
2Y
+134.0%
5Y
+104.5%
All
Overview
- Market Cap
- $119.09B
- Volume
- 66.73K
- 52 Week Range
- $367 – $530
- Total Shares
- 253.81M
- Float Shares
- 253.07M
- Short %
- 2.20%
- % Held by Insiders
- 0.20%
- % Held by Institutions
- 97.95%
- RVOL
- 0.04x
- Beta
- 0.29
Pipeline stages · 14 programs
Biological/Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-121/TEZ/D-IVA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Inaxaplin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Suzetrigine, Pregabalin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-670
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-264
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-993, Pregabalin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ELX/TEZ/IVA, IVA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CTX001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-880
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 14 programs · 4 more ▾
VX-407
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Povetacicept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VX-147
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VNZ/TEZ/D-IVA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 24 trials · 24 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-17 Estimated 50% readout ~2026-12-01 | Phase 3 | Biological/Vaccine | Type 1 Diabetes, Kidney Transplant | — | recruiting |
| 2026-10-30 Estimated 50% readout ~2027-01-13 | Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | — | active not recruiting |
| 2026-12-30 Estimated 50% readout ~2027-02-13 | Phase 2 | Inaxaplin | Proteinuric Kidney Disease | — | active not recruiting |
| 2027-01-25 Estimated 50% readout ~2027-04-10 | Phase 3 | Suzetrigine | Diabetic Peripheral Neuropathic Pain | — | active not recruiting |
| 2027-02-02 Estimated 50% readout ~2027-03-19 | Phase 1/2 | VX-670 | Myotonic Dystrophy Type 1 (DM1) | — | recruiting |
Show all 24 trials · 19 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-12 Estimated 50% readout ~2027-04-26 | Phase 1/2 | VX-264 | Type 1 Diabetes | — | active not recruiting |
| 2027-03-25 Estimated 50% readout ~2027-05-09 | Phase 2 | VX-993, Pregabalin | Diabetic Peripheral Neuropathic Pain | — | recruiting |
| 2027-04-06 Estimated 50% readout ~2027-06-20 | Phase 3 | ELX/TEZ/IVA, IVA | Cystic Fibrosis | — | active not recruiting |
| 2027-04-06 Estimated 50% readout ~2027-06-20 | Phase 3 | Suzetrigine | Diabetic Peripheral Neuropathic Pain | — | recruiting |
| 2027-05-31 Estimated 50% readout ~2027-08-14 | Phase 3 | Suzetrigine, Pregabalin | Diabetic Peripheral Neuropathic Pain | — | recruiting |
| 2027-06-06 Estimated 50% readout ~2027-08-20 | Phase 3 | CTX001 | Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases | — | active not recruiting |
| 2027-06-09 Estimated 50% readout ~2027-08-23 | Phase 3 | CTX001 | Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia | — | recruiting |
| 2027-06-30 Estimated 50% readout ~2027-09-13 | Phase 3 | VX-880 | Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia | — | recruiting |
| 2027-07-22 Estimated 50% readout ~2027-09-05 | Phase 2 | VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-12-14 | Phase 3 | ELX/TEZ/IVA, IVA | Cystic Fibrosis | — | active not recruiting |
| 2027-11-14 Estimated 50% readout ~2028-01-28 | Phase 3 | CTX001 | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies | — | active not recruiting |
| 2028-01-30 Estimated 50% readout ~2028-04-14 | Phase 3 | Povetacicept | Immunoglobulin A Nephropathy | — | active not recruiting |
| 2028-06-02 Estimated 50% readout ~2028-08-16 | Phase 2/3 | VX-147 | Proteinuric Kidney Disease | — | recruiting |
| 2028-12-29 Estimated 50% readout ~2029-03-14 | Phase 2/3 | Povetacicept, Tacrolimus | Primary Membranous Nephropathy | — | recruiting |
| 2029-01-30 Estimated 50% readout ~2029-03-16 | Phase 2 | VX-670 | Myotonic Dystrophy Type 1 (DM1) | — | enrolling by invitation |
| 2029-03-02 Estimated 50% readout ~2029-04-16 | Phase 2 | Povetacicept | Myasthenia Gravis, Generalized | — | recruiting |
| 2029-07-30 Estimated 50% readout ~2029-10-13 | Phase 3 | VNZ/TEZ/D-IVA | Cystic Fibrosis | — | enrolling by invitation |
| 2030-06-30 Estimated 50% readout ~2030-09-13 | Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | — | active not recruiting |
| 2039-09-30 Estimated 50% readout ~2039-12-14 | Phase 3 | CTX001 | Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia | — | enrolling by invitation |
Catalyst news & presentations · 5
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-06partnershipN/A · Vertex entered merger agreement to acquire Crinetics for $85/shareSEC 8-K
- 2026-03-31rolling reviewpovetacicept · Completed rolling BLA submission with priority review voucher for IgANSEC 8-K
- completed on March 31, 2026regulatory submissionFiled (NDA/BLA)povetacicept · Completed rolling BLA submission for potential accelerated approvalSEC 8-K
- 2025-03-28trial discontinuedVX-264 · Phase 1/2 trial will not advance further after results.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $554 (+18% upside) · 23 analysts
- 2026-07-13UBSBuy
- 2026-07-13Truist SecuritiesBuy
- 2026-07-07RBC CapitalOutperform
- 2026-07-07BairdUnderperform
- 2026-05-06BarclaysOverweight
- 2026-05-05Morgan StanleyOverweight
Competitors — Cystic Fibrosis
Recent news
- 2026-07-21BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
- 2026-07-21Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19 - marketscreener.com
- 2026-07-20Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
- 2026-07-20Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating - marketscreener.com
- 2026-07-16Lobbying Update: $1,200,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
- 2026-07-16Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout | AI
- 2026-07-16Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
- 2026-07-16Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.